Apical Hypertrophic Cardiomyopathy (Apical HCM): A Cardiologist's Guide

What Apical HCM Actually Is

Apical hypertrophic cardiomyopathy is the form of HCM where the heart muscle grows abnormally thick at the apex, the pointed bottom tip of the left ventricle, instead of the wall up near the aortic valve where thickening usually concentrates. It is the same underlying disease as classic HCM, just settled in a different spot, and that location changes how it shows up, how we find it, and what we watch for.

If you have read my main guide to hypertrophic cardiomyopathy, you already know the basics: HCM is an inherited condition where heart muscle thickens with no outside cause like high blood pressure or a tight aortic valve. The standard threshold for the diagnosis is muscle that measures 15 millimeters or thicker. In the apical variant, that thickening sits at the tip.

When the apex bulks up, it crowds the bottom of the pumping chamber. On an imaging scan taken in cross-section, the left ventricle ends up shaped like the ace of spades, wide at the top and pinched to a point at the bottom. Cardiologists have called it the “ace of spades sign” for decades, and it remains one of the more satisfying patterns to recognize on a scan.

Apical HCM was first described in Japan in the 1970s, and for years it was thought of as an almost entirely Japanese condition. We now know it occurs everywhere. It just occurs at very different rates. In the United States and Europe it makes up only about 3 to 4 percent of all HCM. In Japan and other parts of East Asia it accounts for 15 to 25 percent. I have several patients with it in my own San Diego practice, which is part of why I wanted to write a guide aimed squarely at this variant rather than folding it into the general HCM discussion.

Why Apical HCM Gets Missed

This variant has a reputation for slipping past the first doctor who looks for it, and there are two good reasons.

The first is the echocardiogram. An echo, the ultrasound of the heart that is almost always the first test we order, has a blind spot. The apex sits farthest from the probe, and the ultrasound beam tends to skim past it or foreshorten the view. A radiologist or cardiologist can look at the images, see a heart that pumps well, and reasonably call it normal while real thickening hides at the tip. This is the single most common reason apical HCM goes unrecognized.

The second reason is the ECG. Apical HCM produces some of the most dramatic ECG patterns in all of cardiology: deep, sharp T-wave inversions in the chest leads, often 10 millimeters or more, which we call “giant” T-wave inversions. The problem is that those same deep inversions are a classic sign of a heart starved of blood. More than one patient with apical HCM has been rushed to the cath lab for a suspected heart attack, only to have clean coronary arteries and a puzzled team. The ECG is a genuine clue to apical HCM, and it is also a setup for misdiagnosis if no one connects it to the muscle at the tip.

How We Make the Diagnosis

Getting the diagnosis right takes the right tests, read by someone thinking about the apex.

The ECG comes first and is often what raises the question. The giant T-wave inversions and high-voltage signs of a thick left ventricle are the tip-off. They are not present in every patient, so a normal ECG does not rule the condition out, but when they show up they should put apical HCM on the list rather than sending everyone straight toward a coronary story.

The echocardiogram is still the workhorse, and we can make it far better at seeing the apex. When the standard images are unclear, adding an injected contrast agent of tiny gas-filled microbubbles lights up the chamber and reveals the thick tip and any cavity that has been squeezed nearly shut. I push for contrast whenever the apex is not crisply seen. On echo, we call it apical HCM when the apical wall measures 15 millimeters or thicker, or when the apex is at least 1.3 times thicker than the wall near the base.

Cardiac MRI is the test that settles the matter, and I order it in nearly every suspected case. A cardiac MRI sees the apex with a clarity echo cannot match. It shows the loss of the normal tapering at the tip, a cavity that obliterates as the heart squeezes, and, most valuable of all, two things echo routinely misses: scar tissue and apical aneurysms. The scar shows up through a technique called late gadolinium enhancement, where a contrast dye lingers in fibrotic muscle and marks it bright. The 2024 American Heart Association and American College of Cardiology guidelines put contrast cardiac MRI at the center of a thorough HCM evaluation, and for the apical variant it is hard to imagine doing this well without one.

There is also a newer wrinkle worth knowing about, because it explains why some patients with very real disease used to be told their hearts were normal. Cardiologists have recognized a group with “relative” apical HCM: people with the full picture of an obliterated apical cavity, the giant T-wave inversions, and apical scar, but whose apical wall measures just under that 15-millimeter line. Using a one-size cutoff misses them. When researchers indexed the measurement to body size and looked at the apex segment by segment, diagnostic accuracy climbed to about 92 percent, compared with 69 percent using the old flat 15-millimeter rule. The lesson I take into clinic is to trust the whole pattern, not a single millimeter reading.

How Apical HCM Is Treated

Here is the reassuring part. Apical HCM is almost always nonobstructive, meaning the thick tip does not block blood leaving the heart the way the septal form often does. That spares these patients the whole arm of HCM care built around relieving obstruction, including the myectomy surgery and alcohol ablation procedures I describe in the main HCM article. Treatment instead follows the 2024 guideline path for nonobstructive HCM with a normal pumping fraction, and it is mostly about easing symptoms and watching for the few features that raise risk.

For symptoms like chest pain with exertion or breathlessness, the first-line medicines are beta-blockers or one of the rate-slowing calcium channel blockers, verapamil or diltiazem. These give the stiff ventricle more time to relax and fill between beats, which is where the trouble in apical HCM mostly lives. If breathlessness lingers, a low dose of a water pill, a diuretic, can be added to take fluid pressure off the lungs. The aim is comfort and capacity, since these drugs manage the condition rather than reverse it.

The role of ACE inhibitors and ARBs for symptoms is not well established here, so I do not reach for them on symptom grounds alone. There is one interesting exception. In younger patients, age 45 or under, who carry a clear sarcomere gene change and have only mild disease so far, the ARB valsartan showed a signal that it may slow the muscle remodeling over time. That is a select group, and I discuss it case by case rather than applying it broadly.

A surgical option exists but is rare. A small number of patients have severe, disabling symptoms that persist despite full medical therapy, usually because the apical cavity has become so small that the heart cannot hold enough blood to pump. At a few highly experienced centers, a transapical myectomy can carve out muscle to enlarge the cavity. The guidelines list it as a possibility for carefully chosen patients with a tiny cavity and preserved function. It is not a routine operation, and it belongs only at centers that do a high volume of HCM surgery.

The Apical Aneurysm: The Risk That Changes Everything

If there is one thing I want a patient with apical HCM to understand, it is the apical aneurysm, because it is the single feature that turns a generally favorable condition into one that needs close attention.

An apical aneurysm is a thin-walled pouch that forms at the very tip of the ventricle. Over years, the chronically squeezed, high-pressure apex can give way into a bulging segment of scarred muscle that no longer contracts. It develops in roughly 13 to 15 percent of people with apical HCM, and cardiac MRI is usually what reveals it, since echo frequently cannot see it. When I find one, my whole approach shifts, for three reasons.

The first is rhythm risk. The rim of scar around an aneurysm is exactly the kind of tissue that can host dangerous fast rhythms from the ventricle. The 2024 guidelines now name an apical aneurysm as a recognized marker of sudden cardiac death risk, enough on its own to put an implantable defibrillator, an ICD, on the table for discussion. About one in five patients with an aneurysm who receive a defibrillator end up getting a life-saving shock from it. When recurrent fast rhythms come from that scar rim, a catheter ablation that burns away the culprit tissue can quiet them down.

The second is clot risk. Blood pools and stagnates inside the still, pouched-out aneurysm, and stagnant blood clots. That clot can break loose and travel to the brain as a stroke. The yearly stroke risk in patients with an aneurysm who are not on a blood thinner runs around 1 percent and climbs with aneurysm size. So when I find a sizable aneurysm, I strongly consider starting an anticoagulant even without atrial fibrillation. In one series, anticoagulated patients who had clots sitting in their aneurysms went on to have no strokes at all, which tells you the treatment works when we use it.

The third is size. A bigger aneurysm, 2 centimeters or larger, carries clearly worse odds, with a 5-year sudden-death event rate near 10 percent and a meaningfully higher stroke and clot rate. That sounds frightening, and the encouraging flip side is that the right care changes the math dramatically. With an appropriate defibrillator and anticoagulation, the death rate in this group has been driven down to roughly 0.8 percent per year. The aneurysm is not a sentence. It is a reason to act, and acting works.

A separate point on rhythm: if you develop atrial fibrillation along with HCM, you need a blood thinner regardless of the usual risk-score math, because HCM raises stroke risk on its own. The stiff apical ventricle also tolerates AFib poorly, since it depends on the atrium’s top-off push to fill, so we treat the rhythm attentively.

What the Long-Term Outlook Looks Like

For decades apical HCM was described as the benign variant, and there is real truth in that, with an important asterisk.

The favorable side is well supported. A 2025 analysis pooling more than 8,000 patients found that apical HCM carried roughly half the risk of major cardiac events and about half the overall death rate compared with other forms of HCM. So on average, this is a better diagnosis to have than the septal forms. Most people with it live a normal life.

The asterisk is that “better on average” is not the same as “nothing to watch.” A long Mayo Clinic study followed nearly 200 apical HCM patients and found their survival, while good, ran a bit below what you would expect for people their age without the condition, and that 6 percent had a sudden-death event, a resuscitated arrest, or an appropriate defibrillator shock over the years. Being older, being female, and having atrial fibrillation at the start tracked with worse outcomes. Another study found that over about eight years, a quarter of apical HCM patients had some adverse cardiac event, with the warning signs being older age, an enlarged left atrium, scar on MRI, and short runs of fast rhythm on a monitor.

The one finding that ties all of this together is the aneurysm. Across studies, patients with an apical aneurysm have a sudden-death rate around three times higher than those without one. That is why I lean so hard on cardiac MRI in this variant. The average statistics are reassuring, and they are averages. The MRI is what tells me which individual sitting in my exam room is in the favorable majority and which one has the feature that needs a defibrillator and a blood thinner.

How I Think About Sudden Death Risk in Apical HCM

Sorting the higher-risk patients from the lower-risk ones is the heart of HCM care, and apical HCM has a quirk that makes the standard tools imperfect.

The widely used HCM sudden-death risk calculator actually scores most apical patients as lower risk than other nonobstructive patients, partly because they tend to have less family history of sudden death. On its face that is good news. The catch is that the calculator does not include the two features that matter most in this variant: the apical aneurysm and the amount of scar on MRI. A calculator that ignores those can give false comfort in exactly the apical patients who need attention.

So I weigh the scar directly. The amount of late gadolinium enhancement on MRI, the bright scar signal, is one of the strongest predictors of dangerous rhythms we have. The 2024 guidelines flag scar involving 15 percent or more of the muscle as a feature that can tip an uncertain defibrillator decision toward yes. Newer data suggest we may be drawing that line too high. A large national registry study published in 2026 found that scar at 9 percent of the muscle already marked a clear jump in risk, and that a meaningful number of sudden-death events happen in patients with scar in the 5 to 15 percent range that the old threshold would wave through. Scar also grows over time, which is one reason the guidelines now favor repeating the MRI periodically rather than relying on a single snapshot.

The practical upshot for a patient: in apical HCM, I do not let a low calculator score end the conversation. I look at the aneurysm, I look at the scar, I look at your rhythm monitor and your family history, and I make the defibrillator decision with you based on the whole picture. When the scar is minimal and there is no aneurysm, that is genuine reassurance. When either is present, we act.

Family Screening Still Applies

Apical HCM is inherited the same way as other HCM, in an autosomal dominant pattern, which means each of your first-degree relatives, your parents, siblings, and children, has a 50 percent chance of carrying the same gene change. They should be screened with an echocardiogram and an ECG, and given how easily the apex hides, I have a low threshold for adding an MRI in a relative whose echo looks clean but whose ECG shows those telltale T-wave inversions. If your family carries an identified gene variant, relatives who test negative can step out of repeated imaging, and those who test positive stay in surveillance. Catching this early, before symptoms, always leaves us with more options.

The Bottom Line

Apical HCM is its own animal within the HCM family. It hides from the echocardiogram, it mimics a heart attack on the ECG, and it usually spares patients the obstruction that drives so much of classic HCM treatment. Most people with it do well. The job of good care is to use cardiac MRI to find the minority with an apical aneurysm or extensive scar, because those are the patients for whom a defibrillator, a blood thinner, and close follow-up turn a worrying picture into a manageable one. If you carry this diagnosis, make sure you have had a quality cardiac MRI, make sure someone is tracking your rhythm and your scar over time, and make sure your relatives have been screened. Done right, this is a condition most patients live a long and full life with.

Frequently Asked Questions

Is apical HCM less dangerous than other types of HCM?

On average, yes. Pooled data show roughly half the rate of major cardiac events and death compared with other HCM forms, and most people with apical HCM live a normal life. That average hides a higher-risk minority, though, mainly the 13 to 15 percent who develop an apical aneurysm or who have extensive scar on MRI. The point of careful imaging and monitoring is to tell which group you are in.

Why did my ECG look like I was having a heart attack?

Apical HCM produces deep “giant” T-wave inversions in the chest leads, and those look almost identical to the pattern of a heart starved of blood. Patients are sometimes sent for emergency heart catheterization, which then shows clean arteries. The ECG is a real clue to apical HCM once someone connects it to thickening at the tip of the heart.

Why do I need a cardiac MRI if I already had an echocardiogram?

The apex is the hardest part of the heart for an echocardiogram to see, so echo can miss apical thickening, scar, and especially an apical aneurysm. Cardiac MRI sees all three clearly. In apical HCM the MRI often changes the plan, which is why I order it in nearly every case even when the echo has already been done.

What is an apical aneurysm and should I worry about it?

It is a thin, pouched-out segment of scarred muscle at the tip of the ventricle that forms in about 13 to 15 percent of apical HCM patients. It matters because it raises the risk of dangerous rhythms and of clots that can cause a stroke. It is not a reason to panic. It is a reason to act, since a defibrillator and a blood thinner in the right patients lower the risk substantially.

Do I need an implantable defibrillator?

Not automatically. Many apical HCM patients never need one. The decision rests on your specific risk features, above all whether you have an apical aneurysm or extensive scar on MRI, plus your rhythm monitoring and family history. The standard risk calculator underestimates risk in this variant because it leaves out the aneurysm and scar, so I weigh those separately with you.

Will I need surgery like other HCM patients?

Very unlikely. The myectomy and alcohol ablation procedures in classic HCM relieve obstruction, and apical HCM is usually nonobstructive, so those do not apply. A rare patient with severe symptoms and a tiny cavity may be considered for a specialized apical myectomy at an expert center, but that is uncommon.

Should my children be tested?

Yes. Apical HCM is inherited in an autosomal dominant pattern, so first-degree relatives have a 50 percent chance of carrying the gene and should have an echocardiogram and ECG. Because the apex hides on echo, I have a low threshold for adding an MRI in a relative whose ECG shows the characteristic T-wave changes.

References

1. Ommen, Steve R., Carolyn Y. Ho, Imran M. Asif, et al. “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy.” Journal of the American College of Cardiology 83, no. 23 (2024): 2324-2405.

2. Braunwald, Eugene. “Hypertrophic Cardiomyopathy.” New England Journal of Medicine 393, no. 10 (2025): 1004-1015.

3. Hughes, Rebecca K., Hunain Shiwani, Stefania Rosmini, et al. “Improved Diagnostic Criteria for Apical Hypertrophic Cardiomyopathy.” JACC: Cardiovascular Imaging 17, no. 4 (2024): 350-365.

4. Kitaoka, Hiroaki, Yoshinori Doi, Susan A. Casey, et al. “Comparison of Prevalence of Apical Hypertrophic Cardiomyopathy in Japan and the United States.” American Journal of Cardiology 92, no. 10 (2003): 1183-1186.

5. Rowin, Ethan J., Barry J. Maron, Tammy S. Haas, et al. “Hypertrophic Cardiomyopathy with Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management.” Journal of the American College of Cardiology 69, no. 7 (2017): 761-773.

6. Lee, Douglas Z. J., Mahshid Montazeri, Raluca Bataiosu, et al. “Clinical Characteristics and Prognostic Importance of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy.” JACC: Cardiovascular Imaging 15, no. 7 (2022): 1201-1212.

7. Klarich, Kyle W., Christine H. Attenhofer Jost, Jutta Binder, et al. “Risk of Death in Long-Term Follow-Up of Patients with Apical Hypertrophic Cardiomyopathy.” American Journal of Cardiology 111, no. 12 (2013): 1784-1791.

8. Lee, Justin V., Maria Emmanuela, Andres Patricio, et al. “Systematic Review and Meta-Analysis Comparing Long-Term Outcomes in Apical Versus Non-Apical Hypertrophic Cardiomyopathy.” American Journal of Cardiology (2025).

9. Kramer, Christopher M., Peter Kolm, and the HCMR Investigators. “Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy.” JAMA (2026).

10. Itzhaki Ben Zadok, Osnat, David Hasdai, Guy Witberg, et al. “Calculated Risk for Sudden Cardiac Death in Patients with Apical Versus Nonobstructive Nonapical Hypertrophic Cardiomyopathy.” American Journal of Cardiology 122, no. 9 (2018): 1574-1580.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.